Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a CBD suppository ease sexual pain? new study aims to find out

NCT ID NCT07271030

Symptom relief Sponsor: London Metropolitan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This study tests whether cannabidiol (CBD) suppositories can reduce pain during sex and improve well-being. Fifty adults who experience sexual pain will be randomly assigned to receive one of three doses of CBD or no treatment for one month. Researchers will measure changes in sexual function, mental well-being, and quality of life at 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cannabidiol (CBD) suppository
What this could lead to
If it works, this could point toward a non-drug option for managing sexual pain and improving quality of life.
What could go wrong
This is a small, early-stage study with only 50 people. It may not show clear benefits, and results may not apply to everyone with sexual pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has previously used cannabidiol in any capacity and has not experienced any allergic reaction * Is experiencing sexual pain * There will be an absence of co occurring difficulties * Has attempted sexual intercourse in the last month * Age 18 years or older * Read and write English * Patient Health Questionnaire 9 screening score range between 0-9 mild * General Anxiety Disorder 7 screening score range between 0-9 mild * There are no restrictions on sex, gender, sexuality, or disability Exclusion Criteria: Has experienced an allergic reaction to cannabidiol in any capacity * Has not attempted sexual intercourse in the last month * Has co occurring difficulties * Aged below 18 years old * Are not experiencing sexual pain * Patient Health Questionnaire 9 screening score range between moderate to severe - 10-27 * General Anxiety Disorder 7 screening score range between 10- 21.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Quality of life are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Psychological Well-Being Sexual Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Quality of life Sexual behavior Sexual pain disorder Well-being, psychological

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • School of Social Sciences and Professions

    RECRUITING

    London, N7 8DB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.